Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cyclin-Dependent Kinase 6 | 5 | 2023 | 28 | 1.960 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2023 | 33 | 1.170 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 22 | 1.040 |
Why?
|
| Neoplasms | 6 | 2023 | 1664 | 1.000 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2023 | 35 | 0.990 |
Why?
|
| Pyruvate Kinase | 3 | 2017 | 5 | 0.900 |
Why?
|
| Phosphofructokinases | 1 | 2023 | 1 | 0.900 |
Why?
|
| Phosphofructokinase-1, Type C | 1 | 2021 | 7 | 0.800 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 48 | 0.780 |
Why?
|
| Cyclin D | 1 | 2020 | 12 | 0.730 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 331 | 0.680 |
Why?
|
| Signal Transduction | 7 | 2023 | 2689 | 0.590 |
Why?
|
| Apoptosis | 3 | 2023 | 1641 | 0.570 |
Why?
|
| Cell Proliferation | 4 | 2023 | 1174 | 0.570 |
Why?
|
| Phosphorylation | 5 | 2023 | 1200 | 0.520 |
Why?
|
| Receptors, Androgen | 3 | 2023 | 34 | 0.510 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 306 | 0.470 |
Why?
|
| Protein Multimerization | 1 | 2013 | 71 | 0.430 |
Why?
|
| Immunotherapy | 3 | 2023 | 215 | 0.420 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 195 | 0.420 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 170 | 0.410 |
Why?
|
| Cell Line, Tumor | 9 | 2023 | 1851 | 0.400 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2023 | 108 | 0.380 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 213 | 0.380 |
Why?
|
| Cyclin D3 | 2 | 2023 | 2 | 0.370 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 562 | 0.350 |
Why?
|
| Proteins | 1 | 2013 | 473 | 0.340 |
Why?
|
| Mice | 9 | 2023 | 8474 | 0.290 |
Why?
|
| Animals | 11 | 2023 | 20880 | 0.280 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1293 | 0.270 |
Why?
|
| Humans | 17 | 2023 | 68549 | 0.260 |
Why?
|
| Androgen Antagonists | 2 | 2023 | 45 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 223 | 0.240 |
Why?
|
| p21-Activated Kinases | 1 | 2023 | 14 | 0.230 |
Why?
|
| Androgens | 1 | 2023 | 41 | 0.230 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2013 | 6 | 0.220 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 12 | 0.220 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2021 | 55 | 0.220 |
Why?
|
| Mice, Transgenic | 2 | 2023 | 1033 | 0.210 |
Why?
|
| Cell Membrane | 2 | 2023 | 524 | 0.210 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2022 | 7 | 0.210 |
Why?
|
| Endopeptidases | 1 | 2022 | 52 | 0.210 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 24 | 0.210 |
Why?
|
| Karyopherins | 1 | 2021 | 11 | 0.200 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2013 | 20 | 0.200 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 57 | 0.200 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 138 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 91 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 90 | 0.190 |
Why?
|
| Autophagy | 1 | 2023 | 208 | 0.190 |
Why?
|
| Mice, SCID | 1 | 2021 | 238 | 0.190 |
Why?
|
| Binding Sites | 2 | 2013 | 631 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 369 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 852 | 0.180 |
Why?
|
| Models, Molecular | 1 | 2021 | 546 | 0.170 |
Why?
|
| Lipogenesis | 1 | 2018 | 9 | 0.170 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2017 | 2 | 0.150 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 508 | 0.150 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 778 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 2791 | 0.150 |
Why?
|
| Phenylthiohydantoin | 2 | 2013 | 12 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 307 | 0.140 |
Why?
|
| Prognosis | 1 | 2021 | 2093 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 214 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 271 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 18 | 0.120 |
Why?
|
| Male | 6 | 2023 | 37283 | 0.120 |
Why?
|
| Cell-Matrix Junctions | 1 | 2013 | 2 | 0.110 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 26 | 0.110 |
Why?
|
| Protein Binding | 2 | 2013 | 1027 | 0.110 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2012 | 6 | 0.110 |
Why?
|
| Cytoskeleton | 1 | 2013 | 84 | 0.110 |
Why?
|
| Calmodulin | 1 | 2013 | 53 | 0.110 |
Why?
|
| Chemokines | 1 | 2013 | 119 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 146 | 0.100 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2012 | 1 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 86 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 304 | 0.100 |
Why?
|
| Cell Movement | 1 | 2013 | 630 | 0.090 |
Why?
|
| Cytoplasm | 1 | 2009 | 155 | 0.080 |
Why?
|
| Cell Line | 1 | 2013 | 1752 | 0.080 |
Why?
|
| Calcium | 1 | 2013 | 929 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2009 | 305 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 1070 | 0.070 |
Why?
|
| Phycocyanin | 1 | 2006 | 1 | 0.070 |
Why?
|
| Aminopyridines | 2 | 2017 | 26 | 0.060 |
Why?
|
| Middle Aged | 1 | 2021 | 21119 | 0.060 |
Why?
|
| Nitriles | 2 | 2013 | 68 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 132 | 0.050 |
Why?
|
| Benzamides | 2 | 2013 | 156 | 0.050 |
Why?
|
| Female | 2 | 2021 | 38021 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2017 | 312 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 87 | 0.050 |
Why?
|
| Protein Transport | 2 | 2013 | 280 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 511 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 266 | 0.040 |
Why?
|
| Microtubules | 2 | 2013 | 104 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 597 | 0.040 |
Why?
|
| Fatty Acid Synthase, Type I | 1 | 2018 | 5 | 0.040 |
Why?
|
| Phosphofructokinase-1 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2017 | 5 | 0.040 |
Why?
|
| Purines | 1 | 2017 | 39 | 0.040 |
Why?
|
| Reactive Nitrogen Species | 1 | 2017 | 32 | 0.040 |
Why?
|
| Serine | 1 | 2017 | 99 | 0.040 |
Why?
|
| Glycolysis | 1 | 2017 | 79 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 659 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 499 | 0.030 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cell Survival | 1 | 2017 | 901 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 167 | 0.030 |
Why?
|
| Castration | 1 | 2012 | 13 | 0.030 |
Why?
|
| Molecular Motor Proteins | 1 | 2013 | 14 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2017 | 718 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2012 | 34 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2013 | 77 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 235 | 0.030 |
Why?
|
| Morpholines | 1 | 2012 | 79 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 132 | 0.030 |
Why?
|
| Quinolines | 1 | 2012 | 48 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 208 | 0.030 |
Why?
|
| Testosterone | 1 | 2012 | 96 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 196 | 0.030 |
Why?
|
| Imidazoles | 1 | 2012 | 175 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2012 | 128 | 0.030 |
Why?
|
| Base Sequence | 1 | 2013 | 1015 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 332 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 1082 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1446 | 0.020 |
Why?
|
| Nuclear Export Signals | 1 | 2009 | 1 | 0.020 |
Why?
|
| ran GTP-Binding Protein | 1 | 2009 | 2 | 0.020 |
Why?
|
| Nuclear Localization Signals | 1 | 2009 | 5 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 455 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2009 | 65 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 981 | 0.020 |
Why?
|
| Mutation | 1 | 2013 | 1213 | 0.020 |
Why?
|
| Tubulin | 1 | 2006 | 60 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2006 | 99 | 0.020 |
Why?
|
| Caspases | 1 | 2006 | 194 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 742 | 0.010 |
Why?
|